Physician's assessment of global response of improvement, clear or excellent ‐ 6 weeks · people with atopic dermatitis
Tacrolimus 0.1% probably leads to higher physician's assessment of global response of improvement, clear or… compared with corticosteroids (moderate certainty).
3 findings from 1 review
RR 3.09 [2.14, 4.45]
1 study · 371 participants
Moderate
RR 0.95 [0.78, 1.16]
1 study · 377 participants
Low
RR 1.32 [1.17, 1.49]
1 study · 972 participants
Moderate
Adverse effects ‐ burning · people with atopic dermatitis
Tacrolimus 0.1% probably leads to higher adverse effects: burning ‐ tacrolimus 0.1% versus hydrocortisone… compared with corticosteroids (moderate certainty).
3 findings from 1 review
RR 2.91 [1.6, 5.28]
1 study · 371 participants
Moderate
RR 4.59 [3.1, 6.78]
1 study · 377 participants
Moderate
RR 3.79 [2.99, 4.81]
1 study · 972 participants
Moderate
Physician's assessment of global response of improvement, clear or excellent ‐ 6 weeks · people with atopic dermatitis
Tacrolimus 0.03% probably leads to higher physician's assessment of global response of improvement, clear or… compared with corticosteroids (moderate certainty).
4 findings from 1 review
RR 2.05 [1.36, 3.08]
1 study · 411 participants
Moderate
RR 2.58 [1.96, 3.38]
2 studies · 790 participants
Moderate
RR 0.45 [0.13, 1.57]
2 studies · 409 participants
Very low
Show 1 more finding
Adverse effects ‐ burning · people with atopic dermatitis
1 finding from 1 review
Participant's self‐assessment of global response of improvement: tacrolimus 0.03% 2x/day versus hydrocortisone acetate 1% 2x/day · people with atopic dermatitis
Tacrolimus 0.03% probably leads to higher participant's self‐assessment of global response of improvement:… compared with corticosteroids (moderate certainty).
1 finding from 1 review
Clinical remission · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus may leads to higher clinical remission compared with placebo (low certainty).
1 finding from 1 review
Clinical improvement · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus showed no clear difference in clinical improvement compared with beclometasone (low certainty).
1 finding from 1 review
Serious adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus showed no clear difference in serious adverse events compared with beclometasone (low certainty).
1 finding from 1 review
Total adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus showed no clear difference in total adverse events compared with beclometasone (low certainty).
1 finding from 1 review
Clinical improvement · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus may leads to higher clinical improvement compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
It is very uncertain whether tacrolimus changes serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Total adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus showed no clear difference in total adverse events compared with placebo (low certainty).
1 finding from 1 review
Clinical remission · adults with refractory, moderate‐to‐severe ulcerative colitis
It is very uncertain whether tacrolimus changes clinical remission compared with ciclosporin (very low certainty).
1 finding from 1 review
Clinical improvement · adults with refractory, moderate‐to‐severe ulcerative colitis
It is very uncertain whether tacrolimus changes clinical improvement compared with ciclosporin (very low certainty).
1 finding from 1 review
Serious adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical remission · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus showed no clear difference in clinical remission compared with beclometasone (low certainty).
1 finding from 1 review
Mortality Mortality at latest · lung transplant recipients
Tacrolimus showed no clear difference in mortality Mortality at latest compared with cyclosporin (low certainty).
1 finding from 1 review
Acute rejection · lung transplant recipients
Tacrolimus showed no clear difference in acute rejection The number of patients who experienced at least one… compared with cyclosporin (low certainty).
1 finding from 1 review
Bronchiolitis obliterans syndrome · lung transplant recipients
Tacrolimus probably leads to lower bronchiolitis obliterans syndrome The number of patients diagnosed… compared with cyclosporin (moderate certainty).
1 finding from 1 review